PPCB
Propanc Biopharma, Inc.
$2.27
-6.58%
$5.2M
No data for this timeframe.
Vol
Market Cap$5.2M
Cap SizeNano Cap
Reddit Sentiment80° Bullish
SEC Reports3
Press Releases5
Recent Activity
Jun 2, 2026
other
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision f
May 19, 2026
Press
Propanc Biopharma engaged a European CDMO for GMP manufacturing of its lead asset PRP, a proenzyme therapy for solid tum
Impact 6/10
May 15, 2026
SEC
Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The company highlighted a
PRESS-RELEASE — Impact 4/10
May 14, 2026
Press
Propanc Biopharma announced a 1-for-25 reverse stock split approved by the board on March 16, 2026, effective May 18, 20
Impact 4/10
Apr 21, 2026
SEC
Propanc Biopharma's IPO registration has become effective, allowing the company to begin selling shares to the public. T
EFFECT — Impact 6/10
Feb 25, 2026
SEC
Analysis based on filing metadata only — document content was unavailable. The filing is an EFFECT form indicating effec
EFFECT — Impact 3/10
Latest Reports
NEUTRAL
Press
6/10
Propanc Biopharma engaged a European CDMO for GMP manufacturing of its lead asset PRP, a proenzyme therapy for solid tum
May 19, 2026
NEUTRAL
PRESS-RELEASE
4/10
Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The company highlighted a
May 15, 2026
NEUTRAL
EFFECT
6/10
Propanc Biopharma's IPO registration has become effective, allowing the company to begin selling shares to the public. T
Apr 21, 2026
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
PRESS-RELEASE
4/10
Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The c
May 15, 2026
NEUTRAL
EFFECT
6/10
Propanc Biopharma's IPO registration has become effective, allowing the company to begin selling sha
Apr 21, 2026
NEUTRAL
EFFECT
3/10
Analysis based on filing metadata only — document content was unavailable. The filing is an EFFECT f
Feb 25, 2026
NEUTRAL
6/10
Propanc Biopharma engaged a European CDMO for GMP manufacturing of its lead asset PRP, a proenzyme t
May 19, 2026
NEUTRAL
4/10
Propanc Biopharma announced a 1-for-25 reverse stock split approved by the board on March 16, 2026,
May 14, 2026
NEUTRAL
4/10
Propanc Biopharma announced a new multi-year research collaboration with the Universities of Jaén an
Mar 24, 2026
NEUTRAL
4/10
Propanc Biopharma announced a service agreement with FyoniBio GmbH to develop and validate a pharmac
Mar 10, 2026
MIXED
6/10
Propanc Biopharma highlighted preclinical and early compassionate-use data for its lead asset PRP, a
Mar 3, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2016-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 11, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 2, 2026
other
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision for the future of humanity are world renowned
May 20, 2026
other
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
These findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance.
May 19, 2026
fda
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study
May 15, 2026
earnings
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
May 14, 2026
activist
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
<p>MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical
May 8, 2026
short_volume
Short Volume: PPCB — 61.5% short (0.4M / 0.6M)
Short: 362,763 | Exempt: 0 | TRF Vol: 590,296 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: PPCB — 56.3% short (0.3M / 0.5M)
Short: 302,244 | Exempt: 0 | TRF Vol: 537,130 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: PPCB — 55.6% short (30.3M / 54.5M)
Short: 30,291,094 | Exempt: 83,407 | TRF Vol: 54,491,173 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: PPCB — 60.3% short (0.6M / 1.0M)
Short: 585,652 | Exempt: 45,802 | TRF Vol: 971,096 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
contract
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases
Mar 23, 2026
short_volume
Short Volume: PPCB — 56.5% short (1.2M / 2.2M)
Short: 1,223,237 | Exempt: 0 | TRF Vol: 2,165,917 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Mar 12, 2026
other
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
Mar 10, 2026
contract
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patie
Mar 3, 2026
fda
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile